Peter Chin, MD
February 23, 2016|Neurology Reviews
Author and Disclosure Information
At the ACTRIMS 2016 Forum, Dr. Chin discussed top-line results from the ORATORIO trial of ocrelizumab in patients with primary progressive MS and also results of a subgroup analysis of patients with gad-enhancing lesions at baseline.